Bay Area's Arcus Biosciences Scores $107M, Initiates Two Clinical Trials
Now totaling $227M, Arcus Biosciences announced it had closed a $107M Series C financing. Source: BioSpace
Now totaling $227M, Arcus Biosciences announced it had closed a $107M Series C financing. Source: BioSpace
Neurotoxicity killed JCAR015 right along with 5 patients in the lead pivotal study, derailing Juno Therapeutics. Source: BioSpace
Investors in beleaguered Argos are smiling this morning after the company announced some positive interim data for its Phase III kidney cancer drug, Rocapuldencel-T - a trial that some said…
Valeant is not the only company to recently push reporters to defy the SEC’s orders. Source: BioSpace
President Donald Trump could be close to naming former Eli Lilly exec Alex Azar as new Secretary of HHS, according to reports. Source: BioSpace
Could GlaxoSmithKline's industry-leading dividend be at risk? Source: BioSpace
The NDA submission is supported by multiple placebo-controlled safety and efficacy studies, as well as two long-term studies that assessed the safety of dasotraline in people with ADHD for up…
Less than one month after announcing plans for construction of a South Carolina manufacturing facility, Arthrex announces its plans for the expansion of its global headquarters in Florida. Source: BioSpace
Abeona Therapeutics has plans to expand its facilities and hire an additional 25 to 40 employees. Source: BioSpace
ImmunoMolecular Therapeputics officially launched yesterday. Source: BioSpace